Biogen Names Priya Singhal as Executive Vice President, Head of Development
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of Research & Development (R&D), has been promoted to Executive Vice President, Head of Development, following a decision to separate Research and Development into two distinct functions that will both report directly to the CEO.
In addition, Biogen has initiated a search for a new Executive Vice President, Head of Research; Dr. Singhal will serve as interim head of Research until a new leader is named.
“Throughout her tenure at Biogen, Priya has demonstrated excellent leadership and judgement. In this new role, Priya will focus on delivering on our development programs while working closely with a new dedicated head of Research to strengthen Biogen’s translational science capabilities,” said Christopher A. Viehbacher, President and Chief Executive Officer of Biogen. “We believe having two dedicated leaders will enhance productivity in bringing to patients worldwide medicines to treat some of the most challenging diseases, while assuring better risk management and resource stewardship.”
Priya Singhal, M.D., M.P.H. – Dr. Singhal most recently served as Senior Vice President and Head of Global Safety and Regulatory Sciences and Interim Head of R&D at Biogen. She also had oversight of Japan and China R&D. Dr. Singhal rejoined Biogen in 2020, having previously led Biogen’s Global Safety and Benefit Risk Management as the interim co-lead and Senior Vice President of Global Development. In this role she managed the worldwide benefit-risk strategy for the portfolio as well as for the filings and approvals of six products. She joined Biogen in late 2012 as Vice President Clinical Trials and Benefit-Risk Management. Prior to her return to Biogen, Dr. Singhal served as Head of R&D and Manufacturing at Zafgen Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases. From 2008-2012 she was at Vertex Pharmaceuticals where she served as the Vice President, Medical Affairs and held roles of increasing seniority in Global Patient Safety. She began her drug-development career at Millennium Pharmaceuticals where she led benefit-risk for Velcade and two compounds in the development portfolio.
Preceding her career in the biotechnology Industry, Dr. Singhal completed her M.P.H. in International Health at Harvard School of Public Health and obtained her training in Internal Medicine in Mumbai, India.
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; the expected benefits from Ms. Singhal’s appointment as Executive Vice President, Head of Development; and the expected benefits from the separation of Research and Development into two distinct functions. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “prospect,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; the potential impact of the conflict in Ukraine; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management and personnel changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements are based on our current beliefs and expectations and speak only as of the date of this news release. We do not undertake any obligation to publicly update any forward-looking statements.
+ 1 210 544 7920
+1 781 464 2442
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Årsrapport for 2022 - Selskabsmeddelelse nr. 1/202327.3.2023 23:07:48 CEST | pressemeddelelse
ÅRSRAPPORT FOR 2022 UDBYTTESTRØM OG LIKVIDITET BEDRE END FORVENTET, TIL TRODS FOR SVÆRE MARKEDER PÅVIRKET AF COVID Hovedpunkter for 2022 - Koncernen Resultat for året blev et tab på DKK 1,5 mio. (DKK -0,5 mio.).Totale pengestrømme for året på DKK -9,1 mio. (2021: positive pengestrømme på DKK 0,8 mio.)Likvide midler pr. 31. december 2022 på DKK 13,0 (DKK 21,9 mio.), heraf DKK 3,5 mio. i moderselskabet EAC Invest, DKK 5,8 mio. i Thailand og DKK 3,7 mio. indestår i Kina og er ikke til umiddelbar disposition for EAC Invest koncernen udenfor Kina.Udbytter fra investeringer udgjorde DKK 3,4 mio., og var lidt højere end oprindeligt forventet.Thai Poly Acrylic var i 2022 hårdt ramt af efterdønninger fra Covid-19 og stigende priser på råmaterialer, hvilket påvirkede salget og resultatet var betydeligt under forventning.Udbyttebetaling på DKK 1.000 pr. aktie og i alt DKK 10 mio. blev gennemført i april 2022. Forventninger for 2023 - Koncernen Forventede driftsomkostninger (primært driftsresultat
Nyxoah Raises $3 Million from an At-the-Market Equity Offering27.3.2023 22:05:00 CEST | Press release
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $3 Million from an At-the-Market Equity Offering Mont-Saint-Guibert, Belgium – March 27, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $2.8 million in gross proceeds pursuant to the Company’s $50 million at-the-market ("ATM") program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The shares were purchased by historical Nyxoah shareholder Cochlear Limited, and the proceeds will be used for general corporate purposes. The ordinary shares described above were sold pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-268955), previously filed with the Securities and Exchange Commission (“SEC
Convocation of the 2023 Annual General Meeting of Shareholders and Proposed Resolutions27.3.2023 20:30:00 CEST | Press release
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014). EINDHOVEN, Pays-Bas et LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, March 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the Company), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today has convened the 2023 Annual General Meeting of Shareholders (AGM), including the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on May 8, 2023. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2022, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2022 statutory accounts were filed with the Netherlands Authority for the Fina
ONWARD Reports 2022 Full Year Financial and Operating Results27.3.2023 20:00:00 CEST | Press release
Company also Provides Business Update and Outlook for 2023 - Conference Call and Webcast (in English) March 28, 2023, at 2:00 PM CEST/8:00 AM EDT THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, LAUSANNE, Switzerland & BOSTON, MA USA, March 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces its 2022 financial and operating results. The full Annual Report is available here, on the Company’s website in the Investors section (https://ir.onwd.com), and on the website of the Netherlands Authority for the Financial Markets (www.afm.nl). “I am proud of the volume and significance of our team’s achievements as we prepare for commercialization of our first therapy in late 2023 or early 2024,” said Dave Marver, CEO
Nokia Corporation: Repurchase of own shares on 27.03.202327.3.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 27 March 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 27.03.2023 Espoo, Finland – On 27 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL284,4184.39CEUX14,3074.40AQEU2904.39TQEX9854.38Total300,0004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and en